The company's fully integrated cross-border R&D platform enables faster, more capital-efficient development of high-quality assets, as demonstrated by Zoci's rapid advancement from first-in-human studies to global pivotal trials. The China commercial business remains a key source of stability and funding for R&D, while the global oncology and immunology pipeline has reached a scale and maturity with a clear path toward the company's first potential U.S. approval by 2028.
Cyborg Score Rationale
2026 is expected to be a defining year with multiple high-impact milestones including Zoci's pivotal program execution, advancement of novel oncology and immunology assets, and anticipated IND filings designed to de-risk the pipeline and accelerate value inflection points. The company has demonstrated strong execution velocity and maintains a profitable China business funding global innovation, though near-term growth is expected to be measured.
Top Insights
Zoci reached global Phase III quickly; pivotal trials plan for 75% enrollment by year-end with about 30% of patients from China.
Expected launch of COBENFY and continued growth of existing product franchises are expected to further strengthen the Company's financial foundation.
Fourth-quarter 2025 revenue increased 17% year-over-year to $127 million, while full-year revenue grew 15% to $460 million.
Management expects a more measured near-term growth profile due to pricing adjustments, hospital purchasing behavior for VYVGART, and intensified competition, with withholding of full-year 2026 guidance despite overall positive revenue and operating leverage.
Named Competitors
Zejula — PARP inhibitor for ovarian cancer
Optune — Tumor Treating Fields for glioblastoma
VYVGART — Antibody for myasthenia gravis
Recent Developments
(March 2026) Q4 2025 earnings: Full-year revenue grew 15% to $460 million; company withheld 2026 guidance citing VYVGART pricing dynamics and hospital purchasing behavior
(January 2026) Outlined 2026 strategic priorities with Zoci Phase III advancement, multiple novel oncology/immunology assets entering clinic, and expected COBENFY China launch
(February 2026) Zoci global Phase III enrollment progressing with 75% enrollment target by year-end and approximately 30% of patients from China
Open the full interactive Zai Lab Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.